## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($363.76)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Alnylam launching $250 million biomanufacturing expansion in Norton**
- Source: The Boston Globe | 20251217T150837 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals is investing $250 million to expand its biomanufacturing facility in Norton, Massachusetts. This expansion follows FDA acceptance of Alnylam's new siRELIS manufacturing platform, which will enable the production of medicines for a wider range of diseases including hypertension, diabetes, and obesity. The investment highlights the growth in biomanufacturing within Greater Boston's life sciences sector.

**2. Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics**
- Source: Business Wire | 20251217T130837 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals announced a $250 million investment to expand its manufacturing facility in Norton, Massachusetts, by adding an enzymatic ligation platform. This expansion aims to significantly increase manufacturing capacity, reduce production costs for RNAi therapeutics, and support future pipeline launches. The company's siRELIS™ platform has been accepted into the FDA’s Emerging Technology Program, highlighting its innovative approach to oligonucleotide-based medicine manufacturing.

**3. Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis**
- Source: Newswire Canada | 20251216T130921 | Bullish | Relevance: 100%
- Alnylam Canada ULC has received Health Canada approval for AMVUTTRA® (vutrisiran), making it the first and only RNAi therapeutic authorized for treating cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). This approval expands AMVUTTRA's indication to include both cardiomyopathy manifestations and polyneuropathy, offering a significant advance for patients with this devastating and often misdiagnosed condition. Based on positive results from the HELIOS-B Phase 3 study, AMVUTTRA® demonstrated significant reductions in mortality and cardiovascular events, and improved functional capacity and quality of life for patients.

**4. Alnylam's $250M Norton facility upgrade aims to slash need for 20 plants down to 2**
- Source: The Business Journals | 20251217T140836 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals is investing $250 million to upgrade its manufacturing facility in Norton. This significant investment is intended to markedly reduce its reliance on numerous external plants, streamlining its production capabilities as it expands into treating more common conditions beyond rare diseases. The upgrade is expected to consolidate operations, potentially cutting the need from 20 plants down to just 2.

**5. Sanders Morris Harris LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY**
- Source: MarketBeat | 20251217T120837 | Bullish | Relevance: 100%
- Sanders Morris Harris LLC has made a new investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), purchasing 3,150 shares valued at approximately $1.44 million in the third quarter. While institutional investors own a significant portion of the stock, recent insider selling by executives has been noted. Analysts have largely given the stock a "Moderate Buy" rating with an average target price of $477.44, with several firms raising their price objectives.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 11.5% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 37.3x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $52.3B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 37.3 |
| Current P/E | 79.8 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -8.1% to -1.9% (+6.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-5.07), momentum weakening. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.87% (CS: 18) | Neutral |
| RSI_14 | 34.2 | Neutral |
| MACD Histogram | -5.07 | Bearish |
| vs SMA20 | 0.922x | Below |
| vs SMA50 | 0.885x | Below |
| vs SMA200 | 1.086x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $396.04
- **Stop Loss:** $363.76 (8.2% risk)
- **Target:** $428.32 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $11,485.16
- **Portfolio %:** 11.49%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*